INUSpheresis® therapy is important for the prevention and treatment of autoimmune diseases.
This treatment method removes faulty autoimmune antibodies and inflammatory mediators from the blood.
This helps to maintain a healthy immunological balance.
INUSpheresis® has been shown to reduce inflammatory markers, which has a positive impact on therapeutic efficacy and can lead to an improvement in overall health.
We achieve several goals with INUSpheresis®/blood washing: We specifically wash disease- and inflammation-causing environmental toxins out of the blood.
In addition, we halve the remaining inflammatory mediators per INUSpheresis®; we therefore reduce the inflammation by approx. 50 % per session.
We also filter out malformed autoimmune antibodies and viral particles (e.g. hepatitis C and HIV).
We therefore do not counteract the rapidly increasing phenomenon of autoimmune diseases worldwide with “anti” drugs that have many side effects, but instead specifically remove their triggering factors such as environmental toxins, inflammatory mediators and malformed autoimmune antibodies.
In autoimmune diseases, the immune system mistakenly attacks its own body as it loses its tolerance to the body’s own tissue structures.
This leads to a misdirected immune response in which the immune system can no longer distinguish between “foreign” and “self”, resulting in autoimmunity.
Organ-related autoimmune diseases affect specific organs, while systemic autoimmune diseases can affect the entire body.
This can lead to chronic inflammation and, in the worst case, to the destruction of the affected organs.
The causes of autoimmune diseases are diverse and complex, with various factors contributing to their development.
The immunological balance is disturbed and the life-sustaining immune function becomes unbalanced.
In the treatment of autoimmune diseases, medicine often attempts to regulate or suppress the body’s own immune response.
This often involves the use of immunosuppressants or corticosteroids, which have an anti-inflammatory effect but can also have undesirable side effects.
We always follow our D – T – A concept. Before we draw up a treatment plan together with our patients, it is important to make a diagnosis in advance based on the patient’s medical history. After approx. 7 to 10 days, the laboratory results provide a picture on which the treatment plan can be based.
As a rule, two INUSpheresis® treatments are initially carried out within 72 hours. After the 2nd INUSpheresis®, therapy is continued with further infusions or molecular medication as required. The determination of the genetic degree of inflammation, which is measured in the “genetic cytokine polymorphism”, is also useful in this context. Patients with a genetically increased degree of inflammation generally require more apheresis for successful treatment than patients with a genetically low degree of inflammation. Due to the outstanding importance of the pro-inflammatory key cytokines TNF-α and IL-1 as well as their counterpart IL-1RN for the individual inflammatory tendency, it has become established to grade the inflammatory tendency based on the respective genetic constellations of a patient.
Patients with an inflammation grade of 0 and 1 are referred to as low-responders, as they have a normal inflammatory capacity. In grade 3 and 4 patients, so-called high-responders, on the other hand, there is a genetically determined strong increase in inflammation. Studies have shown the importance of the IL-1 or TNF-α genotype in a number of systemic inflammatory diseases, such as diabetes, multiple sclerosis, chronic bronchitis, asthma, chronic inflammatory bowel disease, periostitis, osteomyelitis or osteoporosis.
Our aim is to restore the function and communication of your cells and your immune system to a normal state.
Follow us on social media to be informed about current service news!